KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) EBT Margin (2016 - 2025)

Travere Therapeutics' EBT Margin history spans 13 years, with the latest figure at 16.24% for Q4 2025.

  • For Q4 2025, EBT Margin rose 6444.0% year-over-year to 16.24%; the TTM value through Dec 2025 reached 13.47%, up 12399.0%, while the annual FY2025 figure was 10.04%, 12741.0% up from the prior year.
  • EBT Margin reached 16.24% in Q4 2025 per TVTX's latest filing, down from 64.28% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 64.28% in Q3 2025 to a low of 348.94% in Q1 2022.
  • Average EBT Margin over 5 years is 166.93%, with a median of 128.55% recorded in 2024.
  • Peak YoY movement for EBT Margin: plummeted -23597bps in 2022, then skyrocketed 27775bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 64.72% in 2021, then tumbled by -351bps to 291.67% in 2022, then skyrocketed by 33bps to 196.47% in 2023, then surged by 59bps to 80.68% in 2024, then surged by 80bps to 16.24% in 2025.
  • Per Business Quant, the three most recent readings for TVTX's EBT Margin are 16.24% (Q4 2025), 64.28% (Q3 2025), and 11.13% (Q2 2025).